Sign Out
Hemolytic anemia of the primaquine-sensitivity type has been induced by nitrofurantoin. The hemolysis appears to be linked to a glucose-6-phosphate dehydrogenase deficiency in the affected patients' red blood cells. This deficiency is found in 10% of Negroes and in a small percentage of ethnic groups of Mediterranean and Near-Eastern origin. Any sign of hemolysis is an indication to discontinue the drug. Hemolysis ceases when the drug is withdrawn.
Predisposing conditions such as renal impairment, anemia, diabetes, electrolyte imbalance, vitamin B deficiency, and debilitating disease may enhance the occurrence of peripheral neuropathy.
Peripheral neuropathy may occur with nitrofuratoin therapy; this may become severe or irreversible, a fatality has been reported. If numbness or tingling occurs, discontinue the drug.
